CHICAGO – The FDA might not care that much for the opinions of device makers about when the data are enough to support device approvals, but physicians involved in a study of a third-generation TAVR device are arguing that the data for the Sapien 3 valve are enough to approve the device in intermediate-risk patients. Read More
